Improved Bulbar Function in Amyotrophic Lateral Sclerosis after Nuedexta (dextromethorphan and Quinidine) Treatment
Daehan sin-gyeong-gwa hakoeji/Daehan sin'gyeonggwa haghoeji(2019)
摘要
Nuedexta (dextromethorphan and quinidine) is an Food and Drug Administration approved medication for pseudobulbar affect. Interestingly, this drug was recently reported to improve speech, swallowing, and the ability to handle oral secretions along with emotional lability in amyotrophic lateral sclerosis (ALS) patients with bulbar symptoms. We report a Korean ALS patient whose bulbar function improved after administering Nuedexta for 6 months, extending therapeutic choice of approach in treating ALS patients. J Korean Neurol Assoc 37(2):171-173, 2019
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要